Evaluating Surgical Outcomes Between Estrogen Receptor Positive Invasive Lobular and Invasive Ductal Carcinoma of the Breast-A Propensity Matched Analysis.

O'Connor, Dómhnall J; Davey, Matthew G; McFeetors, Carson; McLaughlin, Ray P; Sweeney, Karl J; Barry, Michael K; Malone, Carmel M; Wahab, Sami Abd El; Lowery, Aoife J; Kerin, Michael J

dc.contributor.author	O'Connor, Dómhnall J
dc.contributor.author	Davey, Matthew G
dc.contributor.author	McFeetors, Carson
dc.contributor.author	McLaughlin, Ray P
dc.contributor.author	Sweeney, Karl J
dc.contributor.author	Barry, Michael K
dc.contributor.author	Malone, Carmel M
dc.contributor.author	Wahab, Sami Abd El
dc.contributor.author	Lowery, Aoife J
dc.contributor.author	Kerin, Michael J
dc.date.accessioned	2024-10-04T13:22:38Z
dc.date.available	2024-10-04T13:22:38Z
dc.date.issued	2024-06-29
dc.identifier.pmid	39127596
dc.identifier.doi	10.1016/j.clbc.2024.06.012
dc.identifier.uri	http://hdl.handle.net/10147/643026
dc.description	Introduction: Invasive lobular carcinoma (ILC) contributes significantly to the global cancer burden and is the most common of the histological "special types" of breast cancer. ILC has unique features setting it apart from the more common invasive ductal carcinoma (IDC). Despite differences, treatment algorithms do not consider histological differences. Aim: To determine the differences in treatment and outcomes of ILC relative to IDC in a strict case-matched cohort study at a tertiary referral, specialist, breast cancer center. Methods: All Estrogen receptor positive (ER+) ILCs from 1999 to 2015 were matched for; age, tumor size, grade, PR/HER2 status, nodal stage and metastases with ER+ IDCs from the same period. Surgical and systemic treatments were assessed along with overall (OS) and disease-free survival (DFS). Results: 762 cases in total were analyzed (1:1 matching; ILC:IDC). ILC cases were more often treated with mastectomy (37.5% vs. 28.6%, P .009) and those who received breast conserving surgery (BCS) more often had an incomplete resection (30.2% vs. 19.6%, P .01). IDC were more often treated with NACT (5.5% vs. 14.4%, P < .001). Mean DFS were similar between ILC and IDC; 148.3 vs. 141.4 months (P .112) but OS was significantly longer in the ILC group; 165.7 vs. 134 months (P .002). This trend was consistent among the subset of patients undergoing BCS. For ILC undergoing BCS, mean DFS was 129.8 vs. 128.3 months for IDC (P .418) and OS was 155.4 and 110.7 months respectively (P < .001). Incomplete resection at the time of index surgery did not alter the disease free or overall survival in either the ILC or IDC patients to a level that reached statistical significance. Conclusion: In this cohort study, the strict matching of ILC and IDCs for a number of prognostic indicators, demonstrates the impact of lobular histology with a clarity not previously observed. ILCs have comparable survival outcomes to patients with IDC but at the expense of more extensive index and revisional surgery. There is a need for awareness of these facts among surgeons and patients for optimal treatment prioritization and provision.	en_US
dc.language.iso	en	en_US
dc.publisher	Elsevier	en_US
dc.rights	Copyright © 2024. Published by Elsevier Inc.
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.subject	Breast Cancer survival	en_US
dc.subject	Histological subtype	en_US
dc.subject	neoadjuvant chemotherapy	en_US
dc.subject	Patient tailored treatment	en_US
dc.subject	Tumour micro environment	en_US
dc.title	Evaluating Surgical Outcomes Between Estrogen Receptor Positive Invasive Lobular and Invasive Ductal Carcinoma of the Breast-A Propensity Matched Analysis.	en_US
dc.type	Article In Press	en_US
dc.identifier.eissn	1938-0666
dc.identifier.journal	Clinical breast cancer	en_US
dc.source.journaltitle	Clinical breast cancer
dc.source.country	United States